Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated

22 Oct 2026 0 comments

Data from the real-world, CONFIDENCE study found switching from intravenous to subcutaneous ocrelizumab was well tolerated in patients with relapsing and primary progressive MS.

Source: NeurologyLive Published 22 Oct 2026 Imported 22 Oct 2026 Relevancy: Not reviewed

Read the article

Comments

No comments yet.

Unrestricted

All comments are reviewed before being published. Most comments are approved unless they are clearly inappropriate or unsafe.

Comments

Leave a comment